Aldeyra Therapeutics
ALDX · Nasdaq · United States
Share price · ALDX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026-15.0%
Nothing announced by ALDX that day or the session before.
- 14 Oct 2026-12.2%
Nothing announced by ALDX that day or the session before.
- 5 Oct 2026-21.1%
Nothing announced by ALDX that day or the session before.
- 2 Oct 2026-9.3%
Nothing announced by ALDX that day or the session before.
- 29 Sep 2026+13.8%
- 24 Sep 2026-9.6%
Nothing announced by ALDX that day or the session before.
- 1 Jul 2026+14.1%
Nothing announced by ALDX that day or the session before.
- 29 Jun 2026+12.0%
Nothing announced by ALDX that day or the session before.
- 23 Mar 2026+23.2%
Nothing announced by ALDX that day or the session before.
- 19 Mar 2026+28.9%
Nothing announced by ALDX that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Reactive aldehyde species (RASP)Small molecule | Dry Eye DiseaseAllergic Conjunctivitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.8M | $41M | $3.8M-$4.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $3.5M | $45M | $5.5M-$4.6M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.4M | $65M | $3.5M-$5.1M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.4M | $59M+ $16M short-term inv. | $7.7M-$7.0M operating cash flow | report ↗ |
| 2025-Q2 | — | $8.5M | $41M+ $41M short-term inv. | $9.8M-$8.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.4M | $50M+ $40M short-term inv. | $9.9M-$12M operating cash flow | report ↗ |
| 2024-Q3 | — | $12M | $68M+ $45M short-term inv. | $15M-$8.0M operating cash flow | report ↗ |
| 2024-Q2 | — | $15M | $71M+ $49M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2024-Q1 | — | $6.2M | $102M+ $31M short-term inv. | $8.1M-$10.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.0M | $143M+ $0 short-term inv. | $8.2M-$8.0M operating cash flow | report ↗ |
| 2023-Q2 | — | $7.0M | $152M+ $0 short-term inv. | $9.0M-$13M operating cash flow | report ↗ |
| 2023-Q1 | — | $11M | $165M+ $0 short-term inv. | $16M-$9.4M operating cash flow | report ↗ |
| 2022-Q3 | — | $12M | $129M+ $57M short-term inv. | $15M-$13M operating cash flow | report ↗ |
| 2022-Q2 | — | $15M | $121M+ $76M short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2022-Q1 | — | $12M | $159M+ $58M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $241M | $16M-$8.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $26M | $70M+ $0 short-term inv. | $8.5M-$33M operating cash flow | report ↗ |
Aldeyra Therapeutics reported no disclosed revenue for FY2025, with R&D spend of $25.66M, down 46.8% YoY. Cash and equivalents totaled $70.04M, and the company reported a net loss of $33.85M, with quarterly net burn of $33.85M.
During the period, the company resubmitted the reproxalap NDA for dry eye disease on June 17, 2025; the FDA subsequently requested that the field trial be submitted, extending the PDUFA target action date to March 16, 2026. AbbVie had not exercised its exclusive option as of February 27, 2026. For ADX-2191, the FDA agreed under a Special Protocol Assessment that a positive randomized trial could support NDA resubmission for primary vitreoretinal lymphoma, with top-line results expected in 2026; a Phase 2/3 trial in retinitis pigmentosa is planned for the first half of 2026. Trials of ADX-248 and ADX-246 are expected to begin in 2026 and 2027, respectively.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $48M | $55M+ $47M short-term inv. | $14M-$43M operating cash flow | report ↗ |
| 2023-FY | — | $29M | $143M+ $0 short-term inv. | $9.4M-$30M operating cash flow | report ↗ |
| 2022-FY | — | $47M | $144M+ $30M short-term inv. | $16M-$57M operating cash flow | report ↗ |
| 2021-FY | — | $45M | $230M+ $0 short-term inv. | $14M-$43M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($664K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | DEPTULA-HICKS DARLENE M · director | Open-market purchase | 7,500 | $0.65 | $5K | Form 4 |
| 2026-11-11 | DOUGLAS RICHARD · director | Open-market purchase | 200,000 | $0.64 | $129K | Form 4 |
| 2026-11-11 | Alfieri Michael · Principal Financial Officer | Open-market purchase | 10,000 | $0.65 | $7K | Form 4 |
| 2026-06-09 | DEPTULA-HICKS DARLENE M · director | Award / grant (derivative) | 84,557 | — | — | Form 4 |
| 2026-06-09 | Bronstein Ben · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-09 | Walker Neal · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-09 | Clark William D · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-09 | Phillips Gary M. · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 124 reporting institutions held 37.3M shares ($60.7M, 61.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Knoll Capital Management, LLC | 5,475,516 | $9.3M |
| 2 | BlackRock, Inc. | 3,763,887 | $6.4M |
| 3 | AQR CAPITAL MANAGEMENT LLC | 2,829,875 | $4.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,363,742 | $4.0M |
| 5 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,152,315 | $3.6M |
| 6 | 683 Capital Management, LLC | 1,500,000 | $2.5M |
| 7 | D. E. Shaw & Co., Inc. | 1,403,990 | $2.4M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1,251,652 | $2.1M |
| 9 | STATE STREET CORP | 1,124,710 | $1.9M |
| 10 | MILLENNIUM MANAGEMENT LLC | 995,243 | $1.7M |
| 11 | JANE STREET GROUP, LLC | 968,891 | $1.6M |
| 12 | ARDSLEY ADVISORY PARTNERS LP | 950,000 | $1.6M |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 863,187 | $1.5M |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 807,778 | $1.4M |
| 15 | JACOBS LEVY EQUITY MANAGEMENT, INC | 796,816 | $1.3M |